A$2.99
0.66% yesterday
Australia, Oct 03, 08:10 am CET
ISIN
AU000000SIG5
Symbol
SIG

Sigma Pharmaceuticals Target price 2025 - Analyst rating & recommendation

Sigma Pharmaceuticals Classifications & Recommendation:

Buy
64%
Hold
29%
Sell
7%

Sigma Pharmaceuticals Price Target

Target Price A$3.26
Price A$2.99
Potential
Number of Estimates 10
10 Analysts have issued a price target Sigma Pharmaceuticals 2026 . The average Sigma Pharmaceuticals target price is A$3.26. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 14 analysts: 9 Analysts recommend Sigma Pharmaceuticals to buy, 4 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Sigma Pharmaceuticals stock has an average upside potential 2026 of . Most analysts recommend the Sigma Pharmaceuticals stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2029

Create a premium account to unlock analyst estimates. Learn more

Jun '25 2026
Estimates
Revenue Billion A$ 6.00 9.92
21.85% 65.32%
EBITDA Margin 0.79% 11.63%
17.93% 1,370.43%
Net Margin 8.83% 7.43%
3,242.29% 15.85%

8 Analysts have issued a sales forecast Sigma Pharmaceuticals 2026 . The average Sigma Pharmaceuticals sales estimate is

A$9.9b
Unlock
. This is
9.67% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
A$11.4b 25.88%
Unlock
, the lowest is
A$6.3b 30.53%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 A$6.0b 21.85%
2026
A$9.9b 65.32%
Unlock
2027
A$10.7b 7.39%
Unlock
2028
A$11.4b 7.45%
Unlock
2029
A$15.6b 36.35%
Unlock

9 Sigma Pharmaceuticals Analysts have issued a net profit forecast 2026. The average Sigma Pharmaceuticals net profit estimate is

A$738m
Unlock
. This is
43.97% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
A$845m 64.99%
Unlock
, the lowest is
A$665m 29.79%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 A$530m 3,928.83%
2026
A$738m 39.20%
Unlock
2027
A$876m 18.71%
Unlock
2028
A$1.0b 15.59%
Unlock
2029
A$1.2b 14.66%
Unlock

Net Margin

2025 8.83% 3,242.29%
2026
7.43% 15.85%
Unlock
2027
8.22% 10.63%
Unlock
2028
8.84% 7.54%
Unlock
2029
7.43% 15.95%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2029

Create a premium account to unlock analyst estimates. Learn more

Jun '25 2026
Estimates
Earnings Per Share A$ 0.05 0.06
600.00% 20.00%
P/E 46.62
EV/Sales 3.68

9 Analysts have issued a Sigma Pharmaceuticals forecast for earnings per share. The average Sigma Pharmaceuticals EPS is

A$0.06
Unlock
. This is
50.00% higher
Unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
A$0.07 75.00%
Unlock
, the lowest is
A$0.06 50.00%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 A$0.05 600.00%
2026
A$0.06 20.00%
Unlock
2027
A$0.08 33.33%
Unlock
2028
A$0.09 12.50%
Unlock
2029
A$0.10 11.11%
Unlock

P/E ratio

Current 74.75 109.76%
2026
46.62 37.63%
Unlock
2027
39.27 15.77%
Unlock
2028
33.98 13.47%
Unlock
2029
29.63 12.80%
Unlock

Based on analysts' sales estimates for 2026, the Sigma Pharmaceuticals stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 4.03 529.69%
2026
3.68 8.72%
Unlock
2027
3.43 6.88%
Unlock
2028
3.19 6.94%
Unlock
2029
2.34 26.66%
Unlock

P/S ratio

Current 3.82 473.25%
2026
3.48 8.82%
Unlock
2027
3.24 6.88%
Unlock
2028
3.02 6.94%
Unlock
2029
2.21 26.66%
Unlock

Current Sigma Pharmaceuticals Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
JEFFERIES
Locked
Locked
Locked Sep 08 2025
MACQUARIE RESEARCH
Locked
Locked
Locked Sep 04 2025
BELL POTTER SECURITIES
Locked
Locked
Locked Aug 27 2025
JEFFERIES
Locked
Locked
Locked Jul 17 2025
JEFFERIES
Locked
Locked
Locked Jul 16 2025
ORD MINNETT
Locked
Locked
Locked May 28 2025
ORD MINNETT
Locked
Locked
Locked May 27 2025
Analyst Rating Date
Locked
JEFFERIES:
Locked
Locked
Sep 08 2025
Locked
MACQUARIE RESEARCH:
Locked
Locked
Sep 04 2025
Locked
BELL POTTER SECURITIES:
Locked
Locked
Aug 27 2025
Locked
JEFFERIES:
Locked
Locked
Jul 17 2025
Locked
JEFFERIES:
Locked
Locked
Jul 16 2025
Locked
ORD MINNETT:
Locked
Locked
May 28 2025
Locked
ORD MINNETT:
Locked
Locked
May 27 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today